Amphion Innovations, a developer of medical and technology businesses, announced its part-owned US partner Motif BioSciences will merge with a private company. The private company holds the intellectual property and rights to a clinical stage antibiotic against MRSA and multi-drug resistant bacteria
Read moreShares in AIM-listed Amphion were flying on Tuesday after the technology business won a key patent decision in the US courts. The company had appealed to the US court of appeal as it felt the '502 patent', owned by its subsidary DataTern, had been infringed by several companies. The federal circuit
Read moreMining and development group Mwana Africa said its Non-Executive Interim Chairman had on Thursday acquired himself £15,068-worth of shares, growing his stake by around a fifth. Stuart Morris, who has been on the board since 2005, paid 2.55p for each of the 590,910 shares. The purchase, which inc
Read moreLONDON (Alliance News) - Bank of England policymakers unanimously decided to leave the key interest rates and asset purchase programme unchanged at the monetary policy meeting held on June 4 and 5, the minutes of the meeting showed Wednesday.
All nine members of the Monetary Policy
LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Wednesday.
-------
FTSE 100 - WINNERS
-------
Royal Dutch Shell, up 1.9%. The oil major and state-owned China National Offshore Oil Corpor
LONDON (Alliance News) - Amphion Innovations PLC Wednesday posted a narrowed pretax loss despite seeing revenue decline in 2013, benefiting from lowered administrative costs. Amphion is a private equity firm that focuses on investments in the medical and technology sectors, as well as intel
Read more